Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
99 Cards in this Set
- Front
- Back
cocaine MOA
|
Blocking reuptake of catecholamines and serotonin reuptake; blocks dopamine transporter (DAT) on nerve membrane
|
|
Cocaine pharmacologic effect
|
1) Initial: euphoria & increased arousal via increase in concentration of dopamine in synaptic cleft in the ventral striatum
2) following the "high" --> netagive feelings and dysphoria (D1 & D2 family receptors sequential) 3) "Crash" = fatigue, prolonged sleep, depression, increased appetite |
|
Cocaine therapeutic uses
|
local anesthetic; topical for ear/nose/throat surgery
|
|
Cocaine Side effects
|
fatal arrhythmias, coronary vasospasm
|
|
Cocaine clearance
|
Spontaneous hydrolysis, plasma esterases, small hepatic contribution
|
|
Amphetamine MOA
|
1) Bind to the pre-synaptic membrane and induce release of neurotransmitter
2) Interact with dopamine containing synaptic vesicles, releasing free dopamine into the nerve terminal 3) Bind DAT, causing it to act in reverse and transport free dopamine out of the nerve terminal |
|
Amphetamine pharmacologic use
|
delays eating (decreases hunger)
|
|
Amphetamine therapeutic use
|
Hyperactivity Attention deficit disorder
Narcolepsy sleep disorders (Use as anorexigenic discontinued due to abuse potential) |
|
Amphetamine side effects
|
High abuse potential
Psychosis resembling paranoid schizophrenia increase BP, reflex bradycardia → risk of arrhythmia Insomnia, nervousness, anorexia, GI pain, headache |
|
Amphetamine clearance
|
primarily excreted unchanged by the kidney (approx
80%). |
|
methamphetamine mOA
|
Increases release of DA & NE (& 5HT at high doses) by interacting w/ reuptake transporter to promote reverse transport from cytoplasm to synaptic cleft
|
|
Methamphetamine clearance
|
primarily excreted unchanged by the kidney (approx
80%). |
|
methylphenidate street name
|
ritalin
|
|
methylphenidate MOA
|
Not well understood, blocks reuptake of dopamine via DAT as well as Norepi transporter
|
|
METHYLPHENIDATE pharmacalogic effects
|
Methylphenidate has strongest effects in prefrontal and perietal cortex, regions involved in attention and mental focus. These same regions are less active in ADHD individuals during attention tasks, and have even been reported to be shrunken in ADHD brains.
|
|
Methylphenidate therapeutic fxns
|
ADHD
Narcolepsy |
|
Methyphenidate side effects
|
Intermediate abuse potential (greater in adults than kids)
Psychosis resembling paranoid schizophrenia Insomnia, nervousness, anorexia, GI pain, headache |
|
If you block the DAT receptor on mice, do they still like cocaine?
|
Yes! B/c cocaine (and other stimulants) are "dirty" drugs, meaning that they also effect serotonin & norepinephrine in addition to dopamine, so even if you block the DAT, they still have serotonin effects AND norepinephrine effects...
ergo, if you block both DAT & SERT (serotonin transporter) the preference is abolished |
|
What is unique about mice w/ NET deletions when given cocaine
|
Mice w/ norepi transporter deletions are supersensitive to the locomotor activating effects of cocaine and amphetamine.
|
|
phentermine MOA
|
Increases release of DA and NE (& 5HT at high doses)
|
|
What is the order of "abuse potential" among drugs?
|
cocaine, amphetamine and methamphetamine (highest abuse potential)
>methylphenidate > sibutramine and phentermine. (lowest) |
|
What is phentermine's therapeutic use?
|
appetite suppressants (short term)
|
|
Phentermine's side effects?
|
Lower abuse potential
Sympathomimetic effects on heart – use caution in pts w/ hx of CV disease |
|
sibutramine moa?
|
Blocking reuptake of catecholamines (NE & DA) and serotonin reuptake
|
|
Sibutramine uses?
|
Long term weight loss via active metabolites of CYP3A4
|
|
Sibutramine side effects?
|
Lower abuse potential
Sympathomimetic effects on heart – use caution in pts w/ hx of CV disease |
|
caffeine MOA
|
competitive antagonism at adenosine receptors
Reduces resting cerebral blood flow generally disinhibits neuronal activity |
|
What is methylxanthine
|
Caffiene
|
|
Caffeine clinical uses?
|
Used in patients with asthma as a bronchodilator
Use in the US has now been markedly curtailed since the development of beta-agonists, inhaled corticosteroids, and leukotriene antagonists. --> off label: Sleep apnea in neonatal units accompanied by bradycardia |
|
Caffeine pharmalogical effects?
|
CAFFIENE together Binds to receptors and is antagonistic--> prevents ADENOSINE FROM BINDING AND ACTIVATING SIGNAL
--> adenosine REDUCES presynaptic release and stabilize NMDA blockade post synpatically, ergo Caffiene induces synaptic release and reduce magnesium blockade --> disinhibit synaptic transmission --> central nervous effects --> increased neuronal activity Systemic: increases electrical impulses and pacemaker function of cardio myocytes (heart fxn & rate!) |
|
What is the order of "abuse potential" among drugs?
|
cocaine, amphetamine and methamphetamine (highest abuse potential)
>methylphenidate > sibutramine and phentermine. (lowest) |
|
What is phentermine's therapeutic use?
|
appetite suppressants (short term)
|
|
Phentermine's side effects?
|
Lower abuse potential
Sympathomimetic effects on heart – use caution in pts w/ hx of CV disease |
|
sibutramine moa?
|
Blocking reuptake of catecholamines (NE & DA) and serotonin reuptake
|
|
Sibutramine uses?
|
Long term weight loss via active metabolites of CYP3A4
|
|
Sibutramine side effects?
|
Lower abuse potential
Sympathomimetic effects on heart – use caution in pts w/ hx of CV disease |
|
caffeine MOA
|
Inhibitor of cyclic nucleotide phosphodiesterases and adenosine receptor antagonists, the latter is believed to be the principal contributor to CNS stimulant effects.
Reduces resting cerebral blood flow generally disinhibits neuronal activity |
|
What is methylxanthine
|
Caffiene
|
|
Caffeine clinical uses?
|
Used in patients with asthma as a bronchodilator
Use in the US has now been markedly curtailed since the development of beta-agonists, inhaled corticosteroids, and leukotriene antagonists. --> off label: Sleep apnea in neonatal units accompanied by bradycardia |
|
Caffeine pharmalogical effects?
|
CAFFIENE together Binds to receptors and is antagonistic--> prevents ADENOSINE FROM BINDING AND ACTIVATING SIGNAL
--> adenosine REDUCES presynaptic release and stabilize NMDA blockade post synpatically, ergo Caffiene induces synaptic release and reduce magnesium blockade --> disinhibit synaptic transmission --> central nervous effects --> increased neuronal activity Systemic: increases electrical impulses and pacemaker function of cardio myocytes (heart fxn & rate!) |
|
Caffeine elimination?
|
hepatic metabolism.
|
|
Caffeine side effects?
|
Tolerance develops to the stimulating effects
Withdrawal syndrome can be identified Fatigue Sedation Headache and nausea (with chronic, high-dose use) |
|
modafinil MOA?
|
Mechanism is unknown, but thought:
Interactions with both dopaminergic and noradrenergic systems have been postulated There are indications that it both inhibits hypothalamic sleep-promoting neurons, and activates pathways promoting wakefulness. |
|
Modafinil therapeutic uses?
|
Narcolepsy
Obstructive sleep apnea Shift work sleep disorder Increased daytime wakefulness produced by modafinil is not followed by a rebound increase in nonREM sleep. |
|
Positives of Modafinil?
|
It has a much lower incidence of stimulant side effects than other drugs
Appears less subject to abuse Does not produce the same degree of symapthomimetic effects as do ampehetamines |
|
Modafinil side effects?
|
High (2x recommended) doses were observed to cause a 9 bpm increase in heart rate and a small increase in BP in healthy subjects.
Caution is advised in patients with cardiovascular problems: MI Unstable angina Left ventricular hypertrophy. CAUSES STEVEN JOHNSON SYNDROME!!! Psych: anxiety, mania, suicidal thinking |
|
Modafinil metabolism?
|
Metabolism (CYP3A4, some enzyme induction)
|
|
LSD moa
|
5HT2-A partial agonist
Also enhances glutamate |
|
LSD pharmacologic side effects?
|
Hallucinations: synesthesias, dilation of time
Euphoria; or “bad trips” Peripheral sympathomimetic signs: increase HR & BP, mydriasis Tolerance, but no withdrawal LSD only: Hallucinogen persisting perception disorder (flashbacks) |
|
What gives you auditory hallucinations?
|
PCP
|
|
LSD MOA
|
5HT2-A partial agonist
5-HT2A activation leads to excitation, in part via enhancement of glutamate actions. |
|
Are all 5-HT2A agonists hallucinoenics?
|
No. Different agonists at the same receptor may couple to different effector systems.
|
|
What is the only hallucinogenic that gives you flashbacks?
|
LSD
|
|
What are physical effects of LSD?
|
dilated pupils
higher body temperature and sweating nausea and loss of appetite increased blood sugar Increased heart rate and blood pressure Sleeplessness dry mouth and tremors |
|
What is appearance of LSD?
|
odorless
colorless slightly bitter |
|
At what doses do LSD produce psychogenic effects?
|
less than 100mg
|
|
Does LSD have withdrawal symptoms?
|
no & its not toxic in the human brain
|
|
Mescaline MOA
|
5HT2-A partial agonists
|
|
Mescaline effects
|
same as LSD
|
|
4methylenedioxyamphetamine street name
|
Ecstasy
|
|
4methylenedioxyamphetamine MOA?
|
5HT2-A partial agonist
5-HT2A activation leads to excitation, in part via enhancement of glutamate actions. |
|
4methylenedioxyamphetamine side effects?
|
Hallucinations: synesthesias, dilation of time
Euphoria; or “bad trips” Peripheral sympathomimetic signs: increase HR & BP, mydriasis Tolerance, but no withdrawal MDMA only: serotonergic neuron degeneration**** |
|
MDMA effects
|
same as LSD
User experiences: extreme changes in mood several different emotions at once swing rapidly from one emotion to another delusions and visual hallucinations Physical effects dilated pupils higher body temperature and sweating nausea and loss of appetite increased blood sugar Increased heart rate and blood pressure Sleeplessness dry mouth and tremors |
|
PCP moa
|
Glutamate antagonist!
(Non-competitive antagonist at NMDA receptors) // schizophrenia |
|
PCP effects
|
PCP can cause visual and AUDITORY hallucinations.
Users commonly exhibit: Hostile and combative behavior Paranoid delusions May be numb and not feel pain Tachycardia Hypertension Sweating **Anesthetic effects can ensue at higher doses **Users can progress from agitated behavior with elevated blood pressure, to coma with paralytic dilation of the pupils. |
|
marijuana MOA
|
Δ-9 tetrahydro-cannabinol (delta-9-THC) is the active ingredient – acts as cannabinoid receptor partial agonist (mainly CB1, but also CB2)
|
|
Marijuana therapeutic uses?
|
Recreational drug
Analgesia Appetite stimulation Anti-nausea Reduction of intraocular pressure Decrease spasticity in MS pts |
|
receptor C1 sites of action and action?
|
Found throughout the brain
Highest amounts in: Basal ganglia Cerebellum Hippocampus Cerebral cortex Also in: Spinal cord Hypothalamus Thalamus Peripheral nerve terminals Testes |
|
CB1 MOA
|
The CB1 receptor couples to Gi/o and its activation:
Inhibits adenylyl cyclase Inhibits neuronal Ca+2 channels Increases K+ conductance |
|
Where is CB2 found?
|
CB2 receptor is found in the periphery on immune system cells (lymphocytes, macrophages) and in the CNS on microglia.
|
|
Marijuana effects?
|
Psychological effects may include:
Euphoric mellow High and giddiness Anxiety Panic (especially with high doses) Time dilation Cognitive and psychomotor impairment ( which may persist beyond the perceived high). also... Analgesia Appetite stimulation Antinauseant action Reduction of intraocular pressure Reduction in spasticity in patients with multiple sclerosis |
|
marijuana clearance
|
Hepatic metabolism (note: metabolites detectable in urine/feces up to 5 weeks post-use)
|
|
Delta-9 tetrahydrocannabinol (Delta-9-THC)
MOA? |
Δ-9 tetrahydro-cannabinol (delta-9-THC) is the active ingredient –
acts as cannabinoid receptor partial agonist (mainly CB1, but also CB2) |
|
Dronabinol MOA
|
Δ-9 tetrahydro-cannabinol (delta-9-THC) is the active ingredient –
acts as cannabinoid receptor partial agonist (mainly CB1, but also CB2) |
|
Do Cannabinoids cause dependence?
|
No. Most likely because of their long half life (1.5 days)
|
|
How do endocannabinoids differ from classical neurotransmitter?
|
1) not synthesized and stored in nerve terminals, and then released when an action potential invades the terminal.
2)depolarization of a post-synaptic cell and the entry of Ca2+, or activation of G-protein coupled glutamate receptors (mGluR) activates enzymes that synthesize endocannabinoids from phospholipids. |
|
How are endocannabinoids scaled down?
|
C1 receptors are also on the presynaptic cleft, ergo they can diffuse back across synatpic cleft to act presynaptically -->inhibits presynaptic terminal to scale down activation
|
|
What are signs of precipitated withdrawal from cannabinoids in humans?
|
Restlessness
Irritability Agitation Insomnia Nausea GI cramps |
|
What are side effects of inhalents?
|
Euphoria
Intoxication (exacerbated by hypoxia and hypercapnea when bagging) Drowsiness Slurred speech Ataxia Disorientation Hallucinations Seizures Coma |
|
What is mescaline MOA?
|
Phenethylamine derivative
5HT2-A partial agonist Also enhances glutamate -->similar to LSD, causes hallucinations, etc |
|
What is unique about MDMA compared to other Phenethylamine derivative
5HT2-A partial agonist? |
It has serotonergic neuron degeneration
|
|
What is dronabinol?
|
ingredient –
acts as cannabinoid receptor partial agonist (mainly CB1, but also CB2) //marijuana |
|
What is acetazolamide? what is its MOA? Where does it work?
|
Carbonic Anhydrase Inhibiting Diuretics
What: Carbonic anhydrase inhibitor. Where: Proximal convoluted tubule. How: Increases solute load in urine by ↓ reabsorption of NaHCO3. |
|
What is pharmacalogic effect of acetazolamide?
|
Net result:
↑ excretion of Na+, K+, HCO3-, phosphate; ↓ excretion of H+ (↑ urine pH). Self-limiting!: Causes metabolic acidosis; also macula densa senses ↑ Na+ in urine → afferent arteriole constriction → ↓GFR. Note: 100% bioavailability. |
|
Therapeutic uses for acetazolamide?
|
*Edema (not 1st line)
*Ocular hypertension (open angle) *Prophylaxis for acute altitude sickness *Epilepsy (mainly absence seizures in adults—metabolic acidosis suppresses CNS) *Correct alkalosis |
|
Side effects of acetazolamide?
|
Hypersensitivity (due to sulfa structure): bone marrow depression, skin rxn, renal lesions.
Overdose: somnolence, paresthesias. Alkalization of urine: *ammonia retention → contraindicated in hepatic cirrhosis/ encephalopathy *precipitation of Ca-phosphate salts →contraindicated in renal stones *worsens preexisting acidosis → contraindicated in hyperchloremic acidosis & severe COPD *↓ urine excretion of weak bases → drug interactions |
|
Elimination of acetazolamide?
|
F = 100%,
elimination--renal t1/2 = 6-9 hrs. |
|
What is dorzolamide?
|
Carbonic anhydrase inhibitor:
Where: Proximal convoluted tubule. How: Increases solute load in urine by ↓ reabsorption of NaHCO3. |
|
What is mannitol? Where does it work and what is its MOA?
|
What: Osmotic diuretic.
Where: Thin descending limb. How: Given in large doses, are freely filtered but undergo limited reabsorption → ↑ solute load in lumen → ↓water reabsorption. |
|
What is pharmacologic effect of mannitol? (i.e. excretion, absorption)
|
Net result: ↑ excretion of nearly all electrolytes (Na+, K+, Ca++, Mg++, Cl-, HCO3-, phosphate)
|
|
What is/are therapautic use for mannitol?
|
*Acute renal failure—prevention & tx (controversial)
*Dialysis disequilibrium (hypoosmolarity of extracellular fluid) *Ocular hypertension*** closed! *Intracranial pressure***** *Estimate GFR *↑renal excretion of toxic |
|
Side effects of mannitol?
|
Expansion of extracellular fluid:
*hyponatremia → headache, nausea, vomiting *contraindicated in heart failure, pulmonary congestion Overdiuresis → hypernatremia, dehydration Contraindicated w/ intracranial bleeding!!!! |
|
pharmokinetics of mannitol?
|
F = 100%,
elimination--renal t1/2 =VERY SHORT |
|
What is mannitol's effect on the gradient?
|
Washes out medullary gradient --> less impact from ADH --> less resorption of water
|
|
Explain furomeside what type of drug is it? where does it act and how?
|
What: Loop diuretic.
Where: Thick ascending limb. How: Inhibits Na/K/2Cl symporter → IMPORTANT: acutely increases systemic venous capacitance (via a renally derived mediator, PGs?) and thus decreases cardiac preload and may reduce pulmonary edema even before diuresis occurs.--> FEEL BETTER BEFORE THEY EVEN GET A DROP OF URINE OUT! |
|
Pharmacologic effects of furomeside?
|
1) ↓positive potential in lumen, so ↑Ca++ & Mg++ excretion;
2) ↓ NaCl in renal medulla → ↓ medullary osmotic gradient → ↓ ability to concentrate urine 3) Blocks NaCl transport into macula densa, so GFR doesn't ↓ ALSO: furosemide has venodilator action that can ↓ dyspnea by ↓ preload |
|
Uses for furomeside?
|
1. Acute pulmonary edema
2 Edema associated with heart failure, cirrhosis, renal failure 3. Hypertension 4. Hypercalcemia--a classic use, but minimal supporting 5. A classic use has been in acute renal failure to convert oliguric to nonoliguric status. This use is not supported by recent meta-analyses—use of furosemide does not improve mortality or decrease the need for transplant or dialysis, and may cause ototoxicity. |
|
Side effects of furomeside?
|
↑systemic venous capacitance → ↓cardiac preload, ↓pulmonary edema
*Hypotension, reduced GFR, circulatory collapse *Hyponatremia *Hypokalemia --> arrythmias! *Metabolic alkalosis (losing H+) *Hypomagnesia *OTTOTIXICITY!!! *Hyperuricemia *increased LDL: HDL & glucose intolerance *Hypersensitivity! |
|
Pharmokinetics of furomeside?
|
RENAL & short half life!
WORK, obviously, from the luminal side of the tubule, and because they are highly bound to plasma proteins must be transported by the proximal tubule organic acid transporter. |